Matrix reloaded as Mylan set for Rx revolutions in India and sequel in China
This article was originally published in Scrip
Executive Summary
Three years after it sealed the acquisition of India's Matrix Laboratories, one of the world's largest suppliers of active pharmaceutical ingredients (APIs), Pittsburgh-based Mylan, the second largest US generics company, has unveiled glimpses of its broader strategy for the emerging markets, starting with India and China.